Drug
Andexanet Alfa
Andexanet Alfa: highest development phase Post-Market, developed by Alexion, United Therapeutics. 2 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Alexion, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| andexanet alfa NCT03661528 | Post-Market | Acute Intracranial Hemorrhage |
| Andexanet alfa (Gen 1 Process 2) NCT03083704 | Phase 1 | Bleeding |
Latest
No recent events.
Follow Andexanet Alfa on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.